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  1 
ABSTRACT  2 
Streptococcus suis is an emerging zoonotic pathogen. Lacking an effective vaccine, 3 
antibiotics remain the main tool to fight against infections caused by these bacteria. We have 4 
previously observed a reserpine-sensitive fluoroquinolone-efflux phenotype in this species. 5 
Here, SatAB and SmrA, two pumps belonging to the ATP Binding Cassette and the Major 6 
Facilitator Superfamily, respectively, have been analyzed in the fluoroquinolone-resistant 7 
clinical isolate BB1013. Genes encoding these pumps were overexpressed constitutively or in 8 
the presence of ciprofloxacin in this strain. However, these genes could not be cloned in 9 
plasmids in E. coli despite strong expression repression. Finally, site directed insertion of 10 
smrA and satAB in the amy locus of Bacillus subtilis chromosome using ligated PCR amplicons 11 
allowed for the functional expression and study of both pumps. Results showed that SatAB is 12 
a narrow spectrum fluoroquinolone exporter (norfloxacin and ciprofloxacin), susceptible to 13 
reserpine, whereas SmrA was not involved in fluoroquinolone extrusion. Direct chromosomal 14 
integration in Bacillus is a novel method for studying efflux pumps from Gram-positive 15 
bacteria, which allowed to demonstrate the implication of SatAB, but not of SmrA, in 16 
fluoroquinolone efflux in S. suis.  17 
  18 
  19 
INTRODUCTION  20 
Streptococcus suis is a worldwide distributed zoonotic agent affecting pig and man (19). 21 
In industrialized countries it is mainly regarded as an important economic burden to the pig 22 
industry that only sporadically causes infections in humans. It is therefore defined as an 23 
occupational zoonosis where risk groups are people in close contact with pigs and pork. 24 
Nevertheless, cases of S. suis meningitis have also been reported in patients with no history of 25 
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contact with live pigs or their products (19, 24). In several developing countries in South East Asia, 26 
S. suis is one of the main causes of meningitis in humans, even though its prevalence is probably 27 
still under-estimated (18, 20, 36). Several outbreaks of S. suis have occurred in China (42). The 28 
largest outbreak took place during the summer of 2005 in Sichuan province, and affected 204 29 
people causing 38 fatalities. Mortality was high as a result of the onset of a Toxic Shock  30 
Syndrome (STSS) similar to the one produced by Group A streptococci (GAS) (37). Consequently, 31 
concern about this pathogen has risen in these areas, and measures to prevent or hinder its 32 
impact are already being taken (18).  33 
Antimicrobial resistance is one of the most concerning phenomena in infectious diseases. 34 
In S. suis, resistance to neomycin, spiramycin, lincomycin, trimethoprimsulphamethoxazole, 35 
erythromycin and tetracycline antibiotics is a common feature (30, 33, 41). Interestingly, genome 36 
comparison of STSS-producing strains has led to the discovery of ICESsuBM4072, a putative mobile 37 
Pathogenicity Island bearing tetracycline resistance determinants TetL and TetO, erythromycin 38 
ribosome methylase ErmB, a chloramphenicol acetyltransferase and a dihydrofolate reductase 39 
(17). Treatment of infections caused by S. suis remain, in general, effective by administration of 40 
beta-lactam antibiotics. Nevertheless, strains showing resistance to this family of drugs have been 41 
reported (14, 33). Fluoroquinolones are the main alternative to beta-lactam antibiotics for 42 
treatment of streptococcal infections (9). We have reported increasing fluoroquinolone (FQ) 43 
resistance among clinical S. suis isolates in Spain (8). Substitutions in the quinolone resistance 44 
determining regions (QRDR) of the genes encoding the antibiotic targets, gyrA and parC, were 45 
identified (8). Interestingly the FQ-resistance phenotype could be partially reduced by the efflux 46 
pump inhibitor reserpine, indicating that efflux may be involved in FQ-resistance in S. suis. Several 47 
efflux pumps conferring resistance to fluoroquinolones have been described in other Gram-48 
positive bacteria. Mainly members of two families of transporters are involved: (i) proteins 49 
belonging to the Major Facilitator Superfamily (MFS), such as Bmr of Bacillus subtilis (27), NorA 50 
of Staphylococcus aureus (38), Lde from Listeria monocytogenes (13), and PmrA in  51 
Streptococcus pneumoniae (12); and (ii) exporters belonging to the vast ATP Binding Cassette 52 
(ABC) family, such as PatA and PatB from S. pneumoniae (26) or LmrA from Lactococcus lactis (39). 53 
Efflux-mediated drug resistance is normally a consequence of overexpression of the genes 54 
encoding the pumps, either through mutations in regulators or in promoter regions thereof (28). 55 
Amino acid substitutions can also lead to resistance through a change in the substrate recognition 56 
of the pump (29, 31).   57 
To date, no FQ efflux pumps have been described in S. suis. Here we report the implication 58 
of SatAB, an ABC transporter homologous to PatA and PatB, in resistance to ciprofloxacin and 59 
norfloxacin in S. suis. Further, intensive study of SmrA, a Major  60 
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Facilitator Superfamily transporter analogous to pneumococcal FQ-efflux pump PmrA, allows for 61 
neglecting its role in FQ-resistance. Study of these pumps was accomplished with a knock-in 62 
strategy, integrating the genes encoding the pumps in monocopy in the chromosome of Bacillus 63 
subtilis 168 under the control of an inducible promoter. This system has proven to be a promising 64 
tool for the study of efflux pumps in Gram-positive bacteria.  65 
  66 
MATERIALS AND METHODS  67 
Bacterial strains, culture conditions and susceptibility testing  68 
The characteristics of the strains and plasmids used in this study are listed in Table 1. B. 69 
subtilis 168 and pDR67 were kindly donated by Tarek Msadek from Institut Pasteur in Paris.   70 
S. suis and S. pneumoniae strains were grown on Columbia sheep blood agar plates, Todd-71 
Hewitt broth and a casein hydrolysate-based medium with 0.3% sucrose (AGCH) as energy source. 72 
B. subtilis 168 was grown on LB. Chloramphenicol was added to a final concentration of 5 μg/ml 73 
and 2.5 μg/ml for B. subtilis and S. pneumoniae transformants respectively. Growth media were 74 
obtained from Oxoid (Oxoid Ltd., Basingstoke, United Kingdom) and Biomérieux (BioMérieux, 75 
France). Chemicals, additives and antibiotics were supplied by Merck (Merck KGaA, Darmstadt, 76 
Germany) and Sigma-Aldrich (Sigma Chemical Co. St Louis, Mo). IPTG was purchased from 77 
Invitrogen (Invitrogen, Carlsbad, CA).   78 
Susceptibility tests were carried out following CLSI guidelines (6). Efflux phenotype 79 
visualization was performed by adding 40 μg of ciprofloxacin, enrofloxacin and levofloxacin, and 80 
100 μg of norfloxacin, in 10 μl volume, to non-impregnated discs that were used for diffusion 81 
antibiograms on standard media with and without 10 μg/ml of reserpine dissolved in acetone. 82 
Non-impregnated and antibiotic discs were obtained from Biomerieux (BioMérieux, France) and 83 
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Oxoid (Oxoid Ltd., Basingstoke, United Kingdom). For sugar assays, API 50CH were obtained from 84 
Biomérieux and used following manufacturer’s instructions.  85 
DNA analysis and manipulation  86 
Primers used in this study were supplied by Roche (Roche, Germany), and SigmaGenosys 87 
(Sigma Chemical Co. St Louis, Mo). A list of the primers used can be found in Table 2. PCRs were 88 
performed using Taq Polymerase from Biotools (B&M Labs, Spain). Phusion polymerase 89 
(Finnzymes, Woburn, MA) was used for the obtention of long amplicons. pCR2.1 and pBAD 90 
plasmids and E. coli IncF’ (Top10) strain were purchased from Invitrogen (Invitrogen, Carlsbad, 91 
CA). Plasmid DNA extraction and purification of  92 
PCR fragments were performed using Plasmid Midi, QIAprep Spin Miniprep, Qiagen PCR 93 
purification or Gel extraction Kits (Qiagen, Inc., Chatworth, California, USA). For plasmid extraction 94 
from S. pneumoniae and S. suis a modified first step with sodium deoxycholate was used as 95 
previously described (35). Automated sequencing was carried out at Secugen S. L. (Madrid, Spain). 96 
Sequence analysis was performed using DNA Strider 1.4f13 (CEA, France), 4Peaks 1.6 (Mek&Tosj, 97 
Netherlands), CLC DNA Workbench Software (Denmark), ClustalW, NEBCutter (40) and NIH online 98 
analysis tools (http://www.ncbi.nlm.nih.gov). Promoter sequence analysis was performed with 99 
Bprom (Softberry Inc. Mount Kisco, NY). Protein modeling was done using Phyre server  100 
(22), and illustrated using PyMol Molecular Graphics System, (Version 1.3, Schrödinger,  101 
LLC.).  102 
RT-PCR  103 
RNA from all strains was obtained from liquid cultures in early exponential phase 104 
(DO600=0.3). When ciprofloxacin was added to the growth media, concentrations used were ¼ of 105 
the MIC of each strain. RNA extractions were performed twice from each strain and condition 106 
using RNA-easy Kit (Qiagen, Inc., Chatworth, California, USA).  107 
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Digestions with DNase were performed following manufacturers instructions. Absence of DNA 108 
was checked through PCR. Several digestions were performed until PCR results obtained were 109 
negative. cDNA was obtained using Superscript III retrotranscriptase (Invitrogen, Carlsbad, CA) 110 
and 6bp random primers. Presence of cDNA was confirmed with conventional PCR. RT-PCR 111 
primers (Table 2) were designed using Allele ID 7.7 software (Premier Biosoft, Palo Alto, CA). Q-112 
PCR was carried out in triplicates using MyiQ thermal cycler (Bio-Rad Laboratories Inc. Spain). 113 
Every condition and strain was tested three times. No primer dimer was obtained in any of the 114 
PCRs. Efficiency of all assays was 100% ± 5%. Results on the expression of smrA and satAB were 115 
normalized using rpoB. Primers rpoB428 and rpoB468R, targeting the rpoB gen of S. pneumoniae, 116 
have been previously described (4).  117 
Cloning of smrA and satAB in B. subtilis chromosome   118 
In order to clone smrA and satAB in pDR67, XbaI and BglII restriction sites were used. 119 
Amplification of the ORFs including their putative RBSs was carried out using primers designed to 120 
bear both restriction sites (Table 2). Plasmid and inserts were digested using XbaI and BglII (Takara 121 
Bio, Inc., Japan) and ligated using T4 DNA ligase (New England Biolabs, Beverley, MA). Ligation 122 
product was directly transformed in B. subtilis using a two-step transformation procedure as 123 
previously described (15). Colonies were phenotypically tested for pDR67 integration in the 124 
chromosome. Briefly, amyE disruption leads to the loss of alpha amylase activity. This can be 125 
evidenced by growth on 1% potato starch and staining with iodine pearls. Clones not showing a 126 
light halo around the colonies were selected, for its amylase activity was lost, presumably because 127 
of pDR67 integration (Figure 5). These observations were confirmed by PCR and sequencing.  128 
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Mobilization of the expression system bearing smrA to pJS3  129 
Streptococcal plasmid pJS3 was amplified by PCR with primers bearing EcoRI and BamHI 130 
restriction sites located close together and facing outwards (Table 2). The product was 131 
phosphorilated using polinucleotide kinase, ligated using T4 DNA ligase and transformed in S. 132 
pneumoniae R6 as previously described (23). The resulting plasmid was called pJS3EB and bore 133 
both restriction sites plus a new unique NdeI site in between. Pspac-lacI and Pspac-smrA-lacI from 134 
strains BB1066 and BB1067 respectively, were amplified using primers with EcoRI and BamHI 135 
restriction sites (Table 2). Both inserts and pJS3EB were digested using EcoRI and BamHI and 136 
ligated with T4 DNA ligase. All enzymes were purchased from New England Biolabs (New England 137 
Biolabs, Beverley, MA).  138 
Influence of pH in the activity of SmrA  139 
LB was used as growth media and pH was adjusted to 5, 6, 7 and 8 adding HCl or NaOH 140 
after autoclaving. Inocula were adjusted to 0.5 MacFarland and diluted 1:200 in the growth 141 
medium. IPTG was added to a final concentration of 1mM. Ciprofloxacin and norfloxacin were 142 
tested covering a wide range of concentrations from subinhibitory to inhibitory (0.02 to 0.3 μg/ml 143 
for ciprofloxacin and from 0.06 to 0.8 μg/ml for norfloxacin). Growth curves were performed in 144 
a Tecan Infinite 200 apparatus (Tecan Group Ltd. Männendorf Switzerland). 24-well plates were 145 
incubated at 37ºC and OD620 measurements were taken every 10 minutes after 15 seconds shaking 146 
with 2.5 mm amplitude.  147 
BIOLOG  148 
Biolog phenomic assays were performed at the Veterinary Laboratories Agency, 149 
Weybridge, UK. Strains were grown on agar plates under selective pressure as described above. 150 
Cell suspensions were prepared as previously described (2) to directly obtain an 81% 151 
transmittance (T). Inoculating fluids were available from Biolog. Inocula were prepared following 152 
manufacturer’s instructions and IPTG was added to a final concentration of 1 mM for B. subtilis 153 
and 0.5 mM for S. pneumoniae. All assays were performed at least twice. Colorimetric readings 154 
were performed during incubation at 37ºC for 48h with OmniLog reader. Kinetic data were 155 
analyzed with OmniLog PM software  156 
(Biolog). Microarrays used in both B. subtilis and S. pneumoniae constructions included PM1 and 157 
2A for carbon pathways, and PM11A to 20B for sensitivity to 240 chemicals at 4 different 158 
concentrations. Furthermore S. pneumoniae constructions were also tested against panels PM9 159 
and 10 for pH and ion/osmotic effects.   160 
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Nucleotide sequence accession numbers  161 
The nucleotide sequences of this study have been deposited in GenBank under the 162 
following accession numbers: smrA, including the promoter region, in BB1001, JF416696; in 163 
BB1002, JF416694; and in BB1013, JF416698; and satRAB in BB1001,  164 
JF416697;  in  BB1002,  JF416695;  and  in  BB1013,  JF416699. 165 
  166 
RESULTS  167 
Efflux is involved in FQ resistance in S. suis  168 
In our previous work S. suis isolates of animal origin showing high level FQ resistance were 169 
studied (8). These isolates carried resistance mutations in the quinolone resistance determining 170 
regions (QRDR) of both gyrA and parC, genes encoding the antibiotic targets. In order to assess 171 
the involvement of drug efflux in the FQ-resistance phenotype, ciprofloxacin MIC were 172 
determined with and without the efflux pump  173 
inhibitor reserpine. Briefly, in all but one resistant isolates, resistance levels were 2 to 4fold lower 174 
in the presence of reserpine, indicating that efflux was involved in FQresistance in these strains. 175 
No decrease in the MIC was observed in any of the FQsusceptible strains in presence of reserpine. 176 
To unequivocally prove these results, a diffusion antibiogram method that enabled a clear 177 
visualization of the efflux phenotype was developed. Custom made antibiogram discs bearing high 178 
concentrations of various fluoroquinolones were used on standard media with and without 179 
reserpine against BB1013, an isolate with ciprofloxacin MICs of 64 and 16 μg/ml in the absence 180 
and presence of reserpine, respectively, known to also carry ParC Ser79Tyr and GyrA Ser81Lys 181 
changes involved in FQ-resistance (8). Clear growth-inhibition zones were obtained to 182 
ciprofloxacin and norfloxacin only when reserpine was added, showing the existence of reserpine-183 
sensitive FQ-efflux. However, resistance to enrofloxacin and levofloxacin was unaffected by 184 
reserpine (Figure 1).  185 
  186 
Identification of smrA and satAB  187 
Three FQ efflux pumps have been widely studied in the close member of the genus S. 188 
pneumoniae. PmrA, first described as a norfloxacin extruder (12), is an MFS transporter, whereas 189 
PatA and PatB are ABC transporters involved in ciprofloxacin and norfloxacin efflux among other 190 
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compounds (26). We searched for homologues of these pumps in the available S. suis genomes, 191 
in order to study their possible implication in FQ resistance in this species.  192 
smrA: an ORF encoding a predicted protein with a 58% identity with PmrA was found in 193 
the genome of S. suis and named smrA. The genetic environment of smrA was analogous to that 194 
of pmrA. Protein modeling of the 401 amino acid-long product, SmrA, revealed a 12 195 
transmembrane segments structure found in most MFS transporters (Figure 3). The complete 196 
sequence of the gene with the corresponding promoter region was obtained from resistant strain 197 
BB1013 and from the two susceptible, genetically unrelated, clinical isolates BB1001, and BB1002 198 
(8). SmrA of BB1013 presented two residue substitutions (Thr107Ala and Ile126Val) when 199 
compared to the susceptible alleles, which were identical between each other (Figure 3). The 200 
promoter region of smrA presented a canonical -35 box (TTGACAA) and Ribosome Binding Site 201 
(RBS) (GGAGG) at positions -66 and -14 (Figure 4). No -10 box was identified. Interestingly, 202 
between the -35 box and the region where the -10 box should be located, a 7-bp inverted repeat, 203 
separated by 5 bp, was found. When any 2 of the 5 bp are erased in silico a sequence resembling 204 
a -10 box is found immediately after the 3’ repeat, suggesting smrA could be regulated the way 205 
bmr is (16). A mutation in the 3’ inverted repeat was found in the sequence of the resistant strain 206 
suggesting a possible deregulation of smrA in  207 
BB1013. Further experiments were focused on elucidating whether overexpression of smrA 208 
or/and the amino acidic substitutions found in SmrABB1013 could be involved in fluoroquinolone 209 
resistance in BB1013.  210 
satA and satB: two homologues of pneumococcal FQ-efflux pumps PatA and PatB, 211 
showing 66% and 67% identity, were identified in S. suis genomes and named SatA and SatB. 212 
Protein modeling revealed an N-terminal transmembrane domain and a Cterminal nucleotide 213 
binding domain structure characteristic of ABC transporters (Figure 3). Interestingly, in contrast 214 
to the pneumococcal organization of the ORFs, in wich these genes seem to be independently 215 
cotranscribed, satA and satB showed in S. suis a classical operon conformation, with both genes 216 
immediately contiguous on the same strand and reading frame. Furthermore, upstream satA and 217 
partly overlapping with it, an ORF coding for a regulator of the MarR family was found and named 218 
satR. To determine if satA and satB were cotranscribed on the same mRNA a PCR from one gene 219 
to the other, using primers SatAIntF and SatBIntR (Table 2) was performed on cDNA from BB1001 220 
and BB1013. A 2 kb fragment was amplified from the cDNA and the control DNA of the two strains, 221 
proving the suspected operon conformation of both ORFs (data not shown). This organization 222 
points to the function of SatA and SatB being intimately related and is in accordance to other 223 
authors suggestion of a heterodimeric SatAB transporter (11). Primers satAF and satBR, amplifying 224 
the whole operon and its regulator, were designed using the available S. suis genomes in GenBank. 225 
 
   12  
  
The sequences of satR and satAB of BB1001, BB1002 and BB1013 were obtained by primer walking 226 
and analyzed. Several amino acid differences, mainly located in the transmembrane segments, 227 
were found among the three alleles of both genes (Figure 4). Interestingly, sequence analysis of 228 
the putative regulator SatR revealed in BB1013 a C238T mutation leading to a premature stop 229 
codon (CAA80TAA) compared to BB1001, BB1002 and GenBank sequences.   230 
  231 
Expression analysis  232 
Efflux pumps can lead to antimicrobial resistance through overexpression. In order to 233 
assess if smrA and satAB where overexpressed in BB1013 levels of mRNA of these pumps were 234 
measured by means of RT-Q-PCR using BB1001 as a control (Figure  235 
2).  236 
Expression of smrA was not significantly different between BB1013 and the control strain 237 
in the absence of fluoroquinolones. When subinhibitory concentrations of ciprofloxacin were 238 
added to the growth culture, to a final concentration of ¼ of the MIC (0,12 μg/ml for BB1001 and 239 
16 μg/ml for BB1013), BB1013 increased the levels of expression of smrA, leading to a statistically 240 
significant four-fold difference between both strains.   241 
Expression of satAB was found to be about fifteen times higher in BB1013 than in the 242 
control strain in the absence of ciprofloxacin. Interestingly, expression was not enhanced, but 243 
mildly repressed by the presence of ciprofloxacin in the growth media.   244 
Expression analysis showed that both pumps were overexpressed in BB1013, either under 245 
induction by ciprofloxacin, as is the case of SmrA, or constitutively as for SatAB. Moreover, these 246 
data suggest that satR acts as a repressor of satAB in S. suis.  247 
  248 
Cloning and expression of smrA and satAB in B. subtilis   249 
Cloning of satAB and smrA in E. coli, as performed successfully with other pumps such as 250 
NorA or Bmr (27, 38), was investigated. All assays were negative when trying to clone the genes 251 
encoding the putative pumps in pCR2.1 plasmid and E. coli IncF’ strain. Cloning under the control 252 
of pBAD promoter was tested. Despite enhanced repression by addition of G-6-P (glucose-6-253 
phosphate) and fucose, cloning of S. suis efflux pumps was unsuccessful in all cases, suggesting a 254 
high toxicity of the insert in a Gram-negative environment. Thus, cloning in B. subtilis was explored 255 
as an alternative strategy.  256 
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pDR67 (21) is a plasmid capable of replicating in E. coli and integrating in  257 
Bacillus subtilis chromosome. It is designed for cloning inserts under the control of the IPTG-258 
inducible promoter Pspac. Expression is tightly repressed by the presence, downstream the insert, 259 
of the promoter’s operator, lacI. Furthermore, repression can be strengthened using lacIq E. coli 260 
strains (such as XL1-Blue). pDR67 bears two homology regions with the non-essential amyE 261 
chromosomal gene of B. subtilis, as well as a chloramphenicol marker suitable for selection in this 262 
species. It can therefore be used for mobilizing constructions obtained in E. coli to a Gram-positive 263 
environment as a single copy in the chromosome. IPTG induction is also feasible in this bacterium.  264 
smrA and satAB were cloned with their corresponding RBS in pDR67 and transformed in 265 
XL1-Blue E. coli. Despite the high levels of repression of the insert, transformation efficiency was 266 
low (data not shown). Furthermore, growth of transformants was evidently impaired and, when 267 
streaking these colonies in new plates, various morphologies were recognizable. These clones did 268 
not seem to be suitable and were not used for further study. Interestingly, for each pump, one 269 
colony was found to be positive to the insert by PCR but did not display toxicity signs. Sequencing 270 
revealed premature stop codons in both inserts suggesting the non-functionality of the pumps as 271 
the reason for the absence of toxicity (satA CAG TAG in the case of satAB operon, and a deletion 272 
of A1008 in smrA leading to a frame shift altering the protein sequence of the following 15 amino 273 
acids and a CTA TAG premature stop codon). These strains were used as controls when needed. 274 
Altogether, our data suggest that a cloning procedure including a passage of smrA and satAB 275 
through E. coli is unfeasible. Thus, the ligation products of satAB from the three strains (BB1001, 276 
BB1002 and BB1013) and smrA from BB1013 with pDR67 were directly transformed into B. subtilis 277 
168. Strains BB1068, B1069 and BB1070 bearing the three different alleles of satAB and BB1067 278 
bearing smrA from BB1013, were obtained (Table 1). Sequencing confirmed that the inserts bore 279 
no mutations affecting the protein sequence. A transformant with the complete cloning system 280 
but no insert, namely BB1066, was obtained and conserved as a control. Last, plasmid pDR67 281 
bearing a non-functional copy of satABBB1002 obtained in E. coli was also transformed in B. subtilis, 282 
giving rise to BB1071, a strain bearing the whole operon but with an interrupted satA gene.   283 
satAB confers resistance to fluoroquinolones. smrA does not smrA:  284 
Antimicrobial susceptibility testing to a wide variety of compounds was performed with 285 
strain BB1067, bearing smrABB1013. Strain BB1066 was used as a control. No differences were found 286 
for any of the antibiotics and toxics tested. Primer walking confirmed the correct sequence of the 287 
insert. RT-PCR was performed proving the induction of the system in this strain (data not shown). 288 
As MFS transporters obtain their energy from the proton gradient between the periplasm and the 289 
cytoplasm, we investigated whether pH of the medium could play a role in the activity of SmrA 290 
against fluoroquinolones. Growth curves on LB medium at pH 5, 6, 7 and 8 were performed. 291 
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Several norfloxacin and ciprofloxacin concentrations, ranging from subinhibitory to inhibitory, 292 
were tested in all pHs in presence of 1mM of IPTG. No significant difference could be observed 293 
when comparing BB1066 and BB1067 in any condition (data not shown). Therefore, our data 294 
suggest that smrA is not involved in fluoroquinolone resistance in S. suis. MFS transporters have 295 
also been described as sugar transporters (25). To test whether smrA could be involved in 296 
carbohydrate import or export API 50CH strips were inoculated with BB1067 with and without 297 
induction and compared to  298 
BB1066. No differences were observed among strains nor conditions, suggesting that SmrA is not 299 
a carbohydrate pump either. In order to determine the natural substrate of smrA, our strains were 300 
tested using BIOLOG, a phenomic array technology allowing to easily test a wide variety of 301 
compounds. A panel of 240 antibiotics and toxic molecules at four different concentrations were 302 
tested on BB1067 under induction conditions, using BB1066 as the control strain. Strikingly, of all 303 
the set of molecules, BB1067 only showed a slight improvement of respiration in one of the 304 
dilutions of minocycline, a drug belonging to the family of tetracyclines (data not shown). 305 
Interestingly minocycline is generally not considered to be a substrate of MFS pumps except for 306 
the case of TetB (7). BIOLOG® panel of carbon pathways was also tested confirming previous 307 
results on sugar usage and adding other compounds to SmrA’s list of non-substrate molecules.    308 
In order to rule out the possibility of SmrA not being active in B. subtilis the construction, 309 
from Pspac to lacI (see Figure 5), was mobilized to Streptococcus pneumoniae R6, a close member 310 
of the genus. pJS3, a plasmid derived from streptococcal native plasmid pMV158 (3), was modified 311 
to bear EcoRI and BamHI restriction sites and named pJS3EB. The constructions in the 312 
chromosome of B. subtilis were amplified by PCR and cloned in pJS3EB using the new restriction 313 
sites, giving rise to plasmids pB1011, containing the empty system (Pspac-lacI) as in BB1066, and 314 
pB1012 with the system and smrABB1013 (Pspac-smrA-lacI), as in BB1067. Strains BB1072, and 315 
BB1073 (Table 1) were obtained by transformation of pB1011 and pB1012 respectively into S. 316 
pneumoniae R6 (see materials and methods). Sequence of the insert was checked. RTPCR was 317 
performed in order to confirm that Pspac was inducible by IPTG in S. pneumoniae. Strains BB1072 318 
and BB1073 were confronted to BIOLOG® panel of antibiotics, carbohydrates and ion/osmotic 319 
effects, and confirmed previous observations on minocycline, proving B. subtilis to be a suitable 320 
model for the study of streptococcal  321 
MFS pumps. The natural substrate of this pump remains, though, elusive.    322 
satAB:  323 
Antimicrobial susceptibility testing to a wide variety of antimicrobials of strains bearing 324 
the three alleles of satAB was performed (data not shown). When IPTG was added to the growth 325 
media to a final concentration of 1mM, strains bearing a functional copy of satAB showed a 326 
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decrease in susceptibility to norfloxacin and ciprofloxacin but not to levofloxacin, enrofloxacin, 327 
moxifloxacin, or nalidixic acid (Table 3). In order to quantitate the effect of SatAB, MICs to 328 
ciprofloxacin and norfloxacin were determined with and without induction with IPTG. All alleles 329 
conferred at least a four-fold decrease in susceptibility to both antibiotics. Interestingly the allele 330 
originated from BB1002 conferred an extra doubling-dilution increase in resistance (up to eight-331 
fold) against norfloxacin, and the allele from BB1013 did so to both norfloxacin and ciprofloxacin.  332 
This points to the diversity in amino acid composition of the three alleles of SatAB as a possible 333 
factor in the levels of resistance through modifications in the affinity for the drug. The addition of 334 
reserpine to the medium reverted the resistance phenotype. No differences were observed 335 
between strain BB1066 bearing the expression system but no insert, and BB1071, bearing 336 
ΔsatABBB1002 confirming the non-functionality of the mutated insert. Fluoroquinolone efflux was 337 
only detected in presence of IPTG proving the system’s tight regulation (Table 2). No other 338 
fluoroquinolone tested was a substrate of satAB, nor were any of the antibiotics belonging to a 339 
variety of other families that were tested (data not shown). SatAB is therefore a narrow spectrum 340 
pump of norfloxacin and ciprofloxacin.    341 
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  342 
DISCUSSION  343 
 Antimicrobial resistance is a major threat in the treatment of infectious diseases. Efflux is a 344 
worrying mechanism of resistance as efflux pumps are genes involved in many basic life functions, 345 
such as osmoregulation, and are hence ubiquitous in bacteria. Furthermore, efflux pumps often 346 
confer resistance to a wide array of unrelated compounds, allowing for a one-step selection of 347 
multi-resistant clones as well as for an undesirable co-selection phenomenon.   348 
Here we present SatAB, an efflux pump involved in fluoroquinolone resistance in S. suis. 349 
We also assessed the involvement of SmrA, an MFS transporter homologous to FQ-efflux pump 350 
PmrA, in this phenotype. Our data show that SatAB but not SmrA is involved in fluoroquinolone 351 
efflux in S. suis.   352 
Expression analysis of both pumps has been performed in clinical isolate BB1013. In the 353 
case of satAB, overexpression was constitutive, probably as a consequence of the loss of function 354 
of SatR due to a premature stop codon in its coding sequence. The expression of smrA was not 355 
significantly different from that of susceptible strain BB1001 in the absence of antibiotic. 356 
Nevertheless, when sub-inhibitory concentrations of ciprofloxacin were added to the media, smrA 357 
was significantly overexpressed in BB1013 as compared to BB1001, while satAB levels of 358 
expression remained stably high. Overexpression of efflux pumps in the presence of ciprofloxacin 359 
has already been observed for transporters not related to the efflux of this drug (26). Therefore, 360 
the link between expression and resistance is not concluding. Genetic approaches, such as 361 
knockout or knock-in mutants, are needed to confirm the implication of a pump in a given 362 
resistance phenotype. Cloning in E. coli is an easy and convenient approach. Interestingly some 363 
MFS pumps from Gram-positive bacteria, such as NorA or Bmr, have been cloned and are 364 
functional in E. coli (27, 38), while others, such as PmrA, have, to our knowledge, never been 365 
cloned in a Gram-negative species, despite the interest this pump raises. Altogether our data 366 
suggest that smrA and satAB are extremely toxic for E. coli. We hypothesize that a cell wall 367 
destabilization due to structural differences between E. coli and S. suis, is at the basis of this 368 
phenomenon. It would be interesting to elucidate the features that make some Gram-positive 369 
MFS pumps, and not others, toxic in Gramnegative bacteria even though they all share the same 370 
basic 12-transmembrane segments structure. When cloning toxicity is an impediment, knock-out 371 
mutants are the main strategy to study and characterize pumps. Nevertheless, tools to perform 372 
these assays have not been developed for all species. Even when available, wild type strains are 373 
often difficult to manipulate, and modifiable laboratory strains might not show the desired efflux 374 
phenotype. In S. suis, although some genetic tools are available (34), DNA transformation in 375 
BB1013 was found to be a bottleneck for further experiments. SmrA and SatAB were found to be 376 
very toxic in E. coli rendering the cloning and further study unviable in this species. A system 377 
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enabling the introduction of SmrA and SatAB pumps, while avoiding toxicity, was needed. pDR67 378 
and B. subtilis 168 were used to effectively obtain knock-in mutants that were suitable for 379 
studying efflux pumps. This system has proven to be a fast, easy and reliable tool in the study of 380 
MFS and ABC transporters of S. suis, and will surely be helpful for the study of other pumps from 381 
different Gram-positive species.   382 
PmrA is an MFS efflux pump from S. pneumoniae that has been, at least for some time, 383 
considered to be the main norfloxacin exporter in this bacterium. Since its first description (12) 384 
PmrA has generally failed to be further related to FQ resistance in either wild type strains or 385 
laboratory mutants (1, 5, 26, 32). Its role in fluoroquinolone resistance remains therefore unclear 386 
and is now questioned. The function of SmrA, the homolog of pneumococcal PmrA in S. suis, was 387 
intensively studied. Our results point to  388 
SmrA as not being involved in fluoroquinolone resistance in BB1013. Among more than 450 389 
compounds tested, only minocycline, an antibiotic from the family of tetracyclines, seemed to be 390 
affected by SmrA. These differences were subtle and further investigations are needed to define 391 
the possible clinical impact of SmrA in minocycline resistance. Nevertheless they where consistent 392 
in genetic constructions both in B. subtilis and S. pneumoniae bearing an inducible copy of the 393 
pump, allowing the inference that the whole expression system works not only for ABC, but for 394 
MFS transporters too. Also, S. pneumoniae seems a suitable species for the use of Pspac-lacI 395 
expression system.   396 
Expression levels of smrA where measured in BB1013. Interestingly, expression of smrA 397 
increased in this strain in the presence of ciprofloxacin. As mentioned above, similar results have 398 
also been observed in S. pneumoniae for other transporters that are not involved in FQ extrusion 399 
(26). S. pneumoniae’s chromosome has been shown to be organized in topology-reacting gene 400 
clusters. DNA relaxation by a gyrase inhibitor modified global gene expression, wich affected both 401 
pmrA (downregulation) and patApatB (up-regulation) in opposite ways (10). It would be 402 
interesting, from both a clinical and a basic research perspective, to elucidate the reasons why a 403 
subset of unrelated transporters are overexpressed when in presence of antibiotics that are not a 404 
substrate thereof. Unraveling whether it is a general response to stress or an indirect consequence 405 
of the effect of fluoroquinolones in the coiling and topology of the chromosome (10) would be of 406 
great interest.   407 
Our results prove that SatAB can extrude the fluoroquinolones norfloxacin and 408 
ciprofloxacin. Interestingly the alleles from both susceptible and resistant strains increased the 409 
levels of resistance to fluoroquinolones when cloned in B. subtilis.  It is unlikely that the natural 410 
function of SatAB is FQ efflux as these antibiotics are fully synthetic. Therefore, other functions of 411 
this transporter are yet to be unveiled. Interestingly, levels of resistance conferred by SatAB 412 
differed depending on the allele. A possible influence of the amino acid differences found among 413 
 
   18  
  
alleles cannot be ruled out. Still, SatAB overexpression seems to be the main requisite to obtain 414 
fluoroquinolone efflux. As it is the case for other pumps, of all fluoroquinolones tested, only 415 
ciprofloxacin and norfloxacin were affected by SatAB. This is interesting from both a 416 
drugdevelopment and a structural point of view as the substrate ciprofloxacin and the 417 
nonsubstrate enrofloxacin only differ in a methyl group.   418 
Altogether our data on SmrA allows neglecting the possibility of it being a fluoroquinolone 419 
efflux pump of clinical relevance. Therefore, in order to further investigate S. suis mechanisms of 420 
FQ-resistance efforts should be directed to characterize in depth SatAB and the discovery of other 421 
possible transporters. Experiments to elucidate the implication of SatAB in other resistant clinical 422 
isolates showing efflux are under way.  423 
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FIGURE LEGENDS  569 
Figure 1  570 
Diffusion antibiograms of BB1013 in media with (A) and without (B) 10 μg/ml of 571 
reserpine. CIP, ciprofloxacin; NOR, norfloxacin; LEV, Levofloxacin; ENR, enrofloxacin. Numbers 572 
indicate the micrograms of antibiotic in the disc.  573 
  574 
Figure 2  575 
  Levels of expression of smrA and satAB in BB1013, compared to BB1001.  576 
Striped bars represent growth on subinhibitory concentrations of ciprofloxacin (1/4 of the  577 
MIC of each strain). Pump expression was normalized against rpoB expression levels.  578 
  579 
Figure 3.  580 
 Protein modeling of SmrA (A and B), SatA (C) and SatB (D). A. Lateral view of SmrA 581 
showing a 12 transmembrane segments structure typical of Major Facilitator Superfamily of 582 
transporters. Arrows show the amino acid substitutions present in BB1013 compared to BB1001 583 
and BB1002. Red and yellow stained residues are  584 
T107A and I126V substitutions respectively. B. view down the channel of SmrA. C and D, 585 
modeling of SatA and B. A six transmembrane segments structure followed by a nucleotide-586 
binding domain is observed in each protein.  587 
  588 
Figure 4  589 
   Figure 4  590 
   A. Promoter region of smrA from BB1001, BB1002 and BB1013.  591 
Canonical -35 box and RBS are highlighted with black boxes. Two 7 bp inverted repeats (arrows) 592 
were found downstream the -35 box, separated by a 5 bp spacing region. in silico studies using 593 
SoftBerry Bprom software and the 133 bp immediately upstream smrA showed that the loss of 594 
 
   26  
  
two base pairs in the spacer region led to the recognition of a previously undetected -10 box 595 
immediately downstream the 3’ repeat (grey box). BB1013 bore three mutations when compared 596 
to FQ-susceptible strains. G-43A is located in the 3’ inverted repeat and could interfere with 597 
regulation of smrA expression. B.  598 
Alignment of the amino acid sequence of SatA and SatB from the three strains. Conserved residues 599 
are represented in black over a white background. Light grey and dark grey backgrounds represent 600 
one and two differences among sequences respectively.  601 
  602 
  603 
Figure 5  604 
A. Schematic representation of smrA and satAB integration in B. subtilis. Open reading 605 
frames are shown as arrows, with the direction of transcription indicated by the arrowhead. 606 
pDR67 bears regions of homology to the nonessential amyE locus of B. subtilis. These gene 607 
fragments are shown as broken arrows. Homologous recombination thereof with the 608 
chromosome allows for pDR67 integration. smrA and satAB amplicons were ligated to pDR67 and 609 
transformed directly in B. subtilis. B. Phenotypic screening of pDR67 integration in the 610 
chromosome. Bacteria are grown on LB containing 1% potato starch. Upper lane: B. subtilis 168 611 
with a functional copy of amyE. Degradation of starch appears as a light unstained halo. Lower 612 
lane: BB1066, with pDR67 disrupting amyE, has no amylase activity. Starch is stained and no light 613 
zone is visible.  614 
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1    
2    
TABLE 1. Strains and plasmids used in this study.  
Strains  Relevant genotype  Description  Source or reference  
S. suis    
BB1001  
Wild type  
    
Fluoroquinolone susceptible  Escudero et al. (8)  
BB1002  Wild type   Fluoroquinolone susceptible  Escudero et al. (8)  
BB1013  Wild type   Fluoroquinolone resistant. Efflux  Escudero et al. (8)  
B. subtilis    
BS168  
Reference strain. Used as recipient strain.  
    
Parental strain  Courtesy Msadek, T.  
BB1066  amyE::PspaclacIΔlacZcat  Control strain  This work  
BB1067  amyE::PspacsmrABB1013lacIΔlacZcat    This work  
BB1068  amyE::PspacsatABBB1001lacIΔlacZcat  Inducible resistance to NOR and CIP  This work  
BB1069  amyE::PspacsatABBB1002lacIΔlacZcat  Inducible resistance to NOR and CIP  This work  
BB1070  amyE::PspacsatABBB1013lacIΔlacZcat  Inducible resistance to NOR and CIP  This work  
BB1071  amyE::PspacΔsatABBB1002lacIΔlacZcat    This work  
S. pneumoniae    
R6  
Reference strain  
    
  Rockefeller Inst.  
BB1072  R6/pB1011  Control strain  This work  
BB1073  R6/pB1012  Strain bearing smrABB1013  This work  
Plasmids    
pJS3  
cat  
    
Replicative in Streptococcus spp.  Ballester et al. (3)  
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pJS3EB  -  EcoRI and BamHI restriction sites  This work  
pB1011  pJS3EB:: PspaclacI  Control plasmid  This work  
pB1012  pJS3EB:: PspacsmrABB1013lacI  Plasmid bearing smrABB1013  This work  
3   
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1    
2    
Table 2. List of primers used in this study.  
Name  Sequence 5 3   Reference  




This work  
satBR  TGACCAGTTCGAATCCACGG  This work  
smrAF  ATGGCTGCTCAGCTTTCTTT  This work  






This work  
satBIntR  CCGCAATGGCATTTCCAAGG  This work  





This work  
satBBglIIStop  GCGCAGATCTACTTTATTCAAACACAAACT  This work  
smrAXbaIRBS  GCTCTAGATTTTGGAGGAATTAAAGGAT  This work  
smrABglIIR  GCAGATCTTCACTACACATCCCTTACTT  This work  
pDR67F  ACATCCAGAACAACCTCTGC  This work  
pDR67R  CTCGTTTCCACCGAATTAGC  This work  





This work  
pJS3BamHI  ATATGGATCCGGAGCTGTAATATAAAAAC  This work  
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pDR67EcoRI  ATGAGAATTCTACACAGCCC  This work  
pDR67BamHI  CAGTGCAGGGATCCTAACTC  This work  
pJS3InsF  AATGTCACTAACCTGCCCCG  This work  
pJS3InsR  TGCCAAAAAGCTTCTGTAGG  This work  
RT-Q-PCR smrARTF    
AAGCAGAATTTGAAGGTG  
  
This work  
smrARTR  AAGGGCATTAACAGATACCG  This work  
satABRTF  AATCCAGAACCTTGTCAT  This work  
satABRTR  AATAATCATCCACCAGAGT  This work  
rpoBsuisF  AACTGGCGAGATCAAGAC  This work  
rpoBsuisR  AACGATGATACGCTCTGC  This work  
rpoBBSF  GGATGGCTACAACTATGAG  This work  
rpoBBSR  GCTTCTGATTCGTATTCTTC  This work  
rpoB428  CGGTTGGTGAATTGCTTGCCAACC  4  
rpoB468R  ACTGCAGCTGTTACAGGACGG  4  
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IR    
 Levofloxacin  
-  I  IR  
BB1066  No insert  0,06  0,06  0,06    0,25  0,25  0,12    0,06   0,06  0,06    0,12  0,12  0,12  
BB1067  smrA BB1013  0,06  0,06  0,06    0,25  0,25  0,12    0,06   0,06  0,06    0,12  0,12  0,12  
BB1068  satABBB1001  0,06  0,25  0,12    0,25  1  0,5    0,06   0,06  0,06    0,12  0,12  0,12  
BB1069  satABBB1002  0,06  0,25  0,12    0,5  2  0,5    0,06   0,06  0,06    0,12  0,12  0,12  
BB1070  satABBB1013  0,06  0,5  0,12    0,25  2  0,5    0,06   0,06  0,06    0,12  0,12  0,12  
BB1071  ΔsatABBB1002  0,06  0,06  0,06    0,25  0,25  0,12    0,06   0,06  0,06    0,12  0,12  0,12  
-, standard media. I, 1mM IPTG added; IR, 1mM IPTG and 10 μg/ml of reserpine added.   
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Figure 1  
Diffusion antibiograms of BB1013 in media with (A) and without (B) 10 μg/ml of reserpine. CIP, 
ciprofloxacin; NOR, norfloxacin; LEV, Levofloxacin; ENR, enrofloxacin. Numbers indicate the micrograms 
of antibiotic in the disc.  
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Figure 2  
  Levels    of    expression    of    smrA    and    satAB    in    BB1013,    compared
    to    BB1001.    Striped    bars    represent    growth    on    
subinhibitory    concentrations    of    ciprofloxacin    (1/4    of    the    MIC    of    
each    strain).    Pump   expression    was    normalized    against    rpoB    expression
    levels.  
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Figure 3.  
  Protein modeling of SmrA (A and B), SatA (C) and SatB (D). A. Lateral view of SmrA showing a 12 
transmembrane segments structure typical of Major Facilitator  
Superfamily of transporters. Arrows show the amino acid substitutions present in BB1013 compared to BB1001 
and BB1002. Red and yellow stained residues are T107A and I126V substitutions respectively. B. view down 
the channel of SmrA. C and D, modeling of SatA and B. A six transmembrane segments structure followed by 
a nucleotide-binding domain is observed in each protein.  
     
 




Figure 4  
 A. Promoter region of smrA from BB1001, BB1002 and BB1013. Canonical 35 box and RBS are highlighted 
with black boxes. Two 7 bp inverted repeats (arrows) were found downstream the -35 box, separated by a 5 bp 
spacing region. in silico studies using SoftBerry Bprom software and the 133 bp immediately upstream smrA 
showed that the loss of two base pairs in the spacer region led to the recognition of a previously undetected -10 
box immediately downstream the 3’ repeat (grey box). BB1013 bore three mutations when compared to FQ-
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susceptible strains. G-43A is located in the 3’ inverted repeat and could interfere with regulation of smrA 
expression. B. Alignment of the amino acid sequence of SatA and SatB from the three strains. Conserved 
residues are represented in black over a white background. Light grey and dark grey backgrounds represent one 
and two differences among sequences respectively.  
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Figure 5  
 A. Schematic representation of smrA and satAB integration in B. subtilis. Open reading frames are shown as 
arrows, with the direction of transcription indicated by the arrowhead. pDR67 bears regions of homology to the 
nonessential amyE locus of B. subtilis. These gene fragments are shown as broken arrows. Homologous 
recombination with the chromosome allows for pDR67 integration. smrA and satAB amplicons were ligated to 
pDR67 and transformed directly in B. subtilis. B. Phenotypic screening of pDR67 integration in the 
chromosome. Bacteria are grown on LB containing 1% potato starch. Upper lane: B. subtilis 168 with a 
functional copy of amyE. Degradation of starch appears as a light unstained halo. Lower lane: BB1066, with 
pDR67 disrupting amyE, has no amylase activity. Starch is stained and no light zone is visible.  
     
 
